Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LYEL - Lyell Immunopharma, Inc.

IEX Last Trade
0.612
-0.738   -120.588%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:21:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$1.35
-0.74
-54.67%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
12%
Profitability 0%
Dept financing 3%
Liquidity 75%
Performance 11%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.03%
1 Month
-32.86%
3 Months
-54.60%
6 Months
-69.96%
1 Year
-71.09%
2 Year
-79.90%
Key data
Stock price
$0.61
P/E Ratio 
-1.77
DAY RANGE
$0.61 - $1.35
EPS 
-$0.83
52 WEEK RANGE
$0.63 - $3.26
52 WEEK CHANGE
-$70.95
MARKET CAP 
371.205 M
YIELD 
N/A
SHARES OUTSTANDING 
256.003 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
2.20
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,740,807
AVERAGE 30 VOLUME 
$1,474,182
Company detail
CEO: Elizabeth Homans
Region: US
Website: lyell.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.

Recent news